A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients

Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Study ID
NCT06361927
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study includes two cohorts, cohort A is for non-squamous NSCLC and cohort B is for squamous NSCLC.

Key Dates

Start date
May 15, 2024
Status verified
Apr 2024
Primary completion
Jun 30, 2025
Completion
Jul 31, 2025

Study Design

Enrollment
120 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: cohort A：dose level 1 of SSGJ-707
  • Experimental: cohort A：dose level 2 of SSGJ-707
  • Experimental: cohort A：dose level 3 of SSGJ-707
  • Experimental: cohort B：dose level 1 of SSGJ-707
  • Experimental: cohort B：dose level 2 of SSGJ-707
    cohort B
  • Experimental: cohort B：dose level 3 of SSGJ-707

Primary Outcome Measure

ORR [ Time Frame: 12 months ]

Central Contacts

Related Studies